Literature DB >> 23465982

FDG PET or PET/CT in patients with pancreatic cancer: when does it add to diagnostic CT or MRI?

Omar Javery1, Paul Shyn, Koenraad Mortele.   

Abstract

OBJECTIVE: Assess the impact of FDG-PET or PET/CT (PI) on pancreatic cancer management when added to CT or MRI (CDI).
MATERIALS AND METHODS: Forty-nine patients underwent 79 PI exams. Discordant findings on PI and CDI were assessed for clinical impact.
RESULTS: Fifteen of 79 PI-CDI pairs were discordant. Ten of 79 PI favorably and 5 of 79 unfavorably altered management. PI favorably altered management more often when ordered for therapy monitoring compared to staging [risk ratio 13.00 (95% CI 1.77-95.30)] or restaging [risk ratio 18.5 (95% CI 2.50-137.22)].
CONCLUSION: PI favorably alters management more often when used for therapy monitoring compared to staging or restaging.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23465982     DOI: 10.1016/j.clinimag.2012.07.005

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  7 in total

Review 1.  Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.

Authors:  Domenico Tamburrino; Deniece Riviere; Mohammad Yaghoobi; Brian R Davidson; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2016-09-15

Review 2.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

3.  Reply to the letter to the editor 'Borderline resectable pancreatic cancer: an evolving concept' by Petrucciani et al.

Authors:  J W Gilbert; B Wolpin; T Clancy; J Wang; H Mamon; A B Shinagare; J Jagannathan; M Rosenthal
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976

Review 4.  Selection criteria in resectable pancreatic cancer: a biological and morphological approach.

Authors:  Domenico Tamburrino; Stefano Partelli; Stefano Crippa; Alberto Manzoni; Angela Maurizi; Massimo Falconi
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

5.  Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer.

Authors:  Jose M Pimiento; Ashley H Davis-Yadley; Richard D Kim; Dung-Tsa Chen; Edward A Eikman; Claudia G Berman; Mokenge P Malafa
Journal:  Clin Nucl Med       Date:  2016-03       Impact factor: 7.794

6.  Usefulness of FDG PET/CT derived parameters in prediction of histopathological finding during the surgery in patients with pancreatic adenocarcinoma.

Authors:  Altay Myssayev; Ayan Myssayev; Reiko Ideguchi; Susumu Eguchi; Tomohiko Adachi; Yorihisa Sumida; Shuichi Tobinaga; Masataka Uetani; Takashi Kudo
Journal:  PLoS One       Date:  2019-01-10       Impact factor: 3.240

Review 7.  Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?

Authors:  Christopher Montemagno; Shamir Cassim; Nicolas De Leiris; Jérôme Durivault; Marc Faraggi; Gilles Pagès
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.